These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 30053724)

  • 21. Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies.
    Debattista J; Grech L; Scerri C; Grech G
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Yörüker EE; Holdenrieder S; Gezer U
    Clin Chim Acta; 2016 Apr; 455():26-32. PubMed ID: 26797671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis.
    Tóth K; Barták BK; Tulassay Z; Molnár B
    Expert Rev Mol Diagn; 2016; 16(2):239-52. PubMed ID: 26652067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-Free DNA in the Management of Colorectal Cancer.
    Harlé A
    Recent Results Cancer Res; 2020; 215():253-261. PubMed ID: 31605233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
    Spindler KG
    Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplexed DNA Methylation Analysis in Colorectal Cancer Using Liquid Biopsy and Its Diagnostic and Predictive Value.
    Pulverer W; Kruusmaa K; Schönthaler S; Huber J; Bitenc M; Bachleitner-Hofmann T; Bhangu JS; Oehler R; Egger G; Weinhäusel A
    Curr Issues Mol Biol; 2021 Oct; 43(3):1419-1435. PubMed ID: 34698107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid biopsy in CNS tumors: Current status & future perspectives.
    Husain N; Husain A; Mishra S; Srivastava P
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future perspectives of circulating tumor DNA in colorectal cancer.
    Nadal C; Winder T; Gerger A; Tougeron D
    Tumour Biol; 2017 May; 39(5):1010428317705749. PubMed ID: 28488528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methods for Measuring ctDNA in Lymphomas.
    Rossi D; Condoluci A; Spina V; Gaidano G
    Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?
    Kahlert C
    Cancer Res; 2019 May; 79(10):2462-2465. PubMed ID: 31043377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection.
    Barták BK; Kalmár A; Galamb O; Wichmann B; Nagy ZB; Tulassay Z; Dank M; Igaz P; Molnár B
    Pathol Oncol Res; 2019 Jul; 25(3):915-923. PubMed ID: 29374860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid Biopsy in Solid Malignancy.
    Scarlotta M; Simsek C; Kim AK
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):284-296. PubMed ID: 30916594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring.
    Tao XY; Li QQ; Zeng Y
    Mol Cancer; 2024 Jul; 23(1):145. PubMed ID: 39014366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
    Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer.
    Wang JJ; Wang X; Song YX; Zhao JH; Sun JX; Shi JX; Wu ZH; Wang ZN
    Dis Markers; 2019; 2019():2587109. PubMed ID: 31275444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
    Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
    PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.
    Siravegna G; Bardelli A
    Mol Oncol; 2016 Mar; 10(3):475-80. PubMed ID: 26774880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer.
    Boysen AK; Sørensen BS; Lefevre AC; Abrantes R; Johansen JS; Jensen BV; Schou JV; Larsen FO; Nielsen D; Taflin H; Gustavson B; Wettergren Y; Sorensen BS; Ree AH; Dueland S; Pallisgaard N; Spindler KL
    Clin Chim Acta; 2018 Dec; 487():107-111. PubMed ID: 30240586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Circulating Tumor DNA in Colorectal Cancer.
    Li H; Lu S; Zhou Z; Zhu X; Shao Y
    Methods Mol Biol; 2023; 2695():227-236. PubMed ID: 37450122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.